These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32931269)

  • 21. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.
    Schmidt DM; McCafferty DG
    Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
    Shen L; Wang B; Wang SP; Ji SK; Fu MJ; Wang SW; Hou WQ; Dai XJ; Liu HM
    J Med Chem; 2024 Jan; 67(2):922-951. PubMed ID: 38214982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
    Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A
    ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
    Fang Y; Liao G; Yu B
    J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.
    Ota Y; Itoh Y; Kaise A; Ohta K; Endo Y; Masuda M; Sowa Y; Sakai T; Suzuki T
    Angew Chem Int Ed Engl; 2016 Dec; 55(52):16115-16118. PubMed ID: 27882656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
    Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
    Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances toward LSD1 inhibitors for cancer therapy.
    Fu X; Zhang P; Yu B
    Future Med Chem; 2017 Jul; 9(11):1227-1242. PubMed ID: 28722477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.
    Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A
    J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts.
    Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Monaldi D; Ruoppolo G; Tilset M; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A
    Eur J Med Chem; 2015 Apr; 94():163-74. PubMed ID: 25768700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
    Ota Y; Kakizawa T; Itoh Y; Suzuki T
    Molecules; 2018 May; 23(5):. PubMed ID: 29734782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors.
    Li Z; Yuan Y; Wang P; Zhang Z; Ma H; Sun Y; Zhang X; Li X; Qiao Y; Zhang F; Su Y; Song J; Xie Z; Li L; Ma L; Ma J; Zhang Z
    Eur J Med Chem; 2023 May; 253():115321. PubMed ID: 37037137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.
    Trifirò P; Cappa A; Brambillasca S; Botrugno OA; Cera MR; Zuffo RD; Dessanti P; Meroni G; Thaler F; Villa M; Minucci S; Mercurio C; Varasi M; Vianello P
    Future Med Chem; 2017 Jul; 9(11):1161-1174. PubMed ID: 28722470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent.
    Vianello P; Botrugno OA; Cappa A; Dal Zuffo R; Dessanti P; Mai A; Marrocco B; Mattevi A; Meroni G; Minucci S; Stazi G; Thaler F; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C
    J Med Chem; 2016 Feb; 59(4):1501-17. PubMed ID: 26702542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
    Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
    Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
    Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
    J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer Drugs of Lysine Specific Histone Demethylase-1 (LSD1) Display Variable Inhibition on Nucleosome Substrates.
    Senanayaka D; Zeng D; Deniz E; Priyankara IK; Helmbreck J; Schneider O; Mardikar A; Uren A; Reiter NJ
    Biochemistry; 2024 Jun; 63(11):1369-1375. PubMed ID: 38742921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity.
    Fioravanti R; Rodriguez V; Caroli J; Chianese U; Benedetti R; Di Bello E; Noce B; Zwergel C; Corinti D; Viña D; Altucci L; Mattevi A; Valente S; Mai A
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):973-985. PubMed ID: 35317680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.